Novavax (NVAX) Non-Current Assets (2010 - 2026)
Novavax (NVAX) posted quarterly Non-Current Assets of $192.3 million for Q1 2026, down 54.74% year-over-year from $425.0 million in Q1 2025, and down 2.97% quarter-over-quarter from $198.2 million in Q4 2025.
Novavax (NVAX) Non-Current Assets (2010 - 2026) Analysis & Trends
Novavax's Non-Current Assets history runs 17 years deep, the most recent figure standing at $192.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 54.74% year-over-year to $192.3 million; the TTM figure through Mar 2026 stood at $1.0 billion (down 51.31% YoY), while the FY2025 annual figure was $198.2 million, down 54.06% from the prior year.
- Non-Current Assets for Q1 2026 stood at $192.3 million, down from $198.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $653.6 million in Q4 2023, with the low at $192.3 million in Q1 2026.
- The 5-year median for Non-Current Assets is $507.5 million (2022), against an average of $481.8 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 34.82% in 2022, then slumped 66.28% in 2025.
- Novavax's Non-Current Assets stood at $555.3 million in 2022, then rose by 17.71% to $653.6 million in 2023, then sank by 33.98% to $431.5 million in 2024, then plunged by 54.06% to $198.2 million in 2025, then declined by 2.97% to $192.3 million in 2026.
- Business Quant data shows NVAX's Non-Current Assets at $192.3 million in Q1 2026, $198.2 million in Q4 2025, and $205.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 184.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 184.48 Mn |
| Mar 31, 2026 | 192.35 Mn |
| Dec 31, 2025 | 198.24 Mn |
| Sep 30, 2025 | 205.30 Mn |
| Jun 30, 2025 | 417.04 Mn |
| Mar 31, 2025 | 424.96 Mn |
| Dec 31, 2024 | 431.48 Mn |
| Sep 30, 2024 | 608.80 Mn |
| Jun 30, 2024 | 615.28 Mn |
| Mar 31, 2024 | 626.41 Mn |
| Dec 31, 2023 | 653.60 Mn |
| Sep 30, 2023 | 650.39 Mn |
| Jun 30, 2023 | 557.49 Mn |
| Mar 31, 2023 | 571.67 Mn |
| Dec 31, 2022 | 555.29 Mn |
| Sep 30, 2022 | 507.47 Mn |
| Jun 30, 2022 | 486.99 Mn |
| Mar 31, 2022 | 487.47 Mn |
| Dec 31, 2021 | 421.63 Mn |
| Sep 30, 2021 | 391.76 Mn |